Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
- W. Geerts, D. Bergqvist, C. Colwell
- MedicineChest
- 1 June 2008
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice…
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy:…
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality.
- A. Cohen, G. Agnelli, M. Spannagl
- MedicineThrombosis and Haemostasis
- 1 October 2007
The estimated total number of symptomatic VTE events (range based on probabilistic sensitivity analysis) per annum within the six EU countries was 465,715; almost three-quarters of all VTE-related deaths were from hospital-acquired VTE.
A prospective study of the incidence of deep‐vein thrombosis within a defined urban population
- M. Nordström, B. Lindblad, D. Bergqvist, T. Kjellström
- MedicineJournal of Internal Medicine
- 1 August 1992
In a prospective study all positive phlebographies within the well‐defined population of the city of MalmÖ, Sweden, during 1987 were studied in order to determine the incidence of deep venous thrombosis (DVT), and risk factors were found to be in accordance with earlier studies.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
- S. Schulman, U. Angerås, D. Bergqvist, B. Eriksson, M. Lassen, W. Fisher
- MedicineJournal of Thrombosis and Haemostasis
- 1 January 2010
A definition of major bleeding that should be applicable to all agents that interfere with hemostasis is developed and is to seek approval from the regulatory authorities to enhance its incorporation into future clinical trial protocols.
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
- D. Bergqvist, G. Agnelli, F. Dietrich-Neto
- MedicineNew England Journal of Medicine
- 28 March 2002
Enoxaparin prophylaxis for four weeks after surgery for abdominal or pelvic cancer is safe and significantly reduces the incidence of venographically demonstrated thrombosis, as compared with enoxapin prophyllaxis for one week.
Prevention and treatment of venous thromboembolism--International Consensus Statement.
- A. Nicolaides, J. Fareed, D. Warwick
- MedicineInternational Angiology
- 1 April 2013
The aim of this document is to provide a clear and concise account of the evidence regarding efficacy or harm for various methods available to prevent and manage venous thromboembolism (VTE).
Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.
- M. Ogren, D. Bergqvist, M. Björck, S. Acosta, H. Eriksson, N. Sternby
- MedicineWorld Journal of Gastroenterology
- 2006
PVT was found to be more common than indicated by previous clinical series and the markedly excess risk in cirrhosis and hepatic carcinoma should warrant an increased awareness in patients for whom prospective studies of directed intervention might be considered.
Heparin-Induced Thrombocytopenia
- A. Nicolaides, J. Fareed, D. Warwick
- Medicine, BiologyAnnales de Biologie Clinique
- 25 March 2013
The treatment consists in discontinuing heparin administration and in setting up an alternative treatment for which two drugs are indicated in France: Orgaran and Refludan.
Secondary arterioenteric fistulation--a systematic literature analysis.
- D. Bergqvist, M. Björck
- MedicineEuropean Journal of Vascular and Endovascular…
- 2009
...
...